JP2010513506A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2010513506A5 JP2010513506A5 JP2009542880A JP2009542880A JP2010513506A5 JP 2010513506 A5 JP2010513506 A5 JP 2010513506A5 JP 2009542880 A JP2009542880 A JP 2009542880A JP 2009542880 A JP2009542880 A JP 2009542880A JP 2010513506 A5 JP2010513506 A5 JP 2010513506A5
- Authority
- JP
- Japan
- Prior art keywords
- composition
- polypeptide
- amino acid
- acid sequence
- seq
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 102000004169 proteins and genes Human genes 0.000 claims description 6
- 108090000623 proteins and genes Proteins 0.000 claims description 6
- 238000000746 purification Methods 0.000 claims description 4
- 239000000203 mixture Substances 0.000 claims 32
- 229920001184 polypeptide Polymers 0.000 claims 29
- 125000003275 alpha amino acid group Chemical group 0.000 claims 24
- 150000001413 amino acids Chemical class 0.000 claims 18
- 101710024845 ACVR2A Proteins 0.000 claims 11
- 230000003042 antagnostic Effects 0.000 claims 9
- 239000005557 antagonist Substances 0.000 claims 9
- 102000037240 fusion proteins Human genes 0.000 claims 7
- 108020001507 fusion proteins Proteins 0.000 claims 7
- 210000003743 Erythrocytes Anatomy 0.000 claims 5
- 102000005606 Activins Human genes 0.000 claims 4
- 108010059616 Activins Proteins 0.000 claims 4
- 210000003324 RBC Anatomy 0.000 claims 4
- 239000000488 activin Substances 0.000 claims 4
- 230000001965 increased Effects 0.000 claims 4
- 230000036499 Half live Effects 0.000 claims 3
- 230000027455 binding Effects 0.000 claims 3
- 239000003446 ligand Substances 0.000 claims 3
- 102000018358 Immunoglobulins Human genes 0.000 claims 2
- 108060003951 Immunoglobulins Proteins 0.000 claims 2
- 102000007562 Serum Albumin Human genes 0.000 claims 2
- 108010071390 Serum Albumin Proteins 0.000 claims 2
- 230000037165 Serum Concentration Effects 0.000 claims 2
- 125000000539 amino acid group Chemical group 0.000 claims 2
- 230000015572 biosynthetic process Effects 0.000 claims 2
- 230000002708 enhancing Effects 0.000 claims 2
- 238000005755 formation reaction Methods 0.000 claims 2
- 230000004068 intracellular signaling Effects 0.000 claims 2
- 125000003473 lipid group Chemical group 0.000 claims 2
- 230000004807 localization Effects 0.000 claims 2
- 210000001519 tissues Anatomy 0.000 claims 2
- 208000007502 Anemia Diseases 0.000 claims 1
- 210000004369 Blood Anatomy 0.000 claims 1
- 102000001554 Hemoglobins Human genes 0.000 claims 1
- 108010054147 Hemoglobins Proteins 0.000 claims 1
- 210000002027 Muscle, Skeletal Anatomy 0.000 claims 1
- 210000002966 Serum Anatomy 0.000 claims 1
- 239000008280 blood Substances 0.000 claims 1
- 239000003814 drug Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 108020001756 ligand binding domains Proteins 0.000 claims 1
- 230000004048 modification Effects 0.000 claims 1
- 238000006011 modification reaction Methods 0.000 claims 1
- 238000004587 chromatography analysis Methods 0.000 description 3
- 229920002684 Sepharose Polymers 0.000 description 2
- 238000001542 size-exclusion chromatography Methods 0.000 description 2
- 238000005277 cation exchange chromatography Methods 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 description 1
- 238000003259 recombinant expression Methods 0.000 description 1
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
- 238000011100 viral filtration Methods 0.000 description 1
Description
Claims (22)
- ヒト患者における赤血球レベルを増加させるための組成物であって、該組成物は、以下:
a)配列番号2に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
b)配列番号3に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
c)配列番号2から選択される少なくとも50の連続するアミノ酸を含むポリペプチド;
d)配列番号16に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
e)配列番号17に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;および
f)配列番号16から選択される少なくとも50の連続するアミノ酸を含むポリペプチド
からなる群より選択される有効量のActRIIポリペプチドを含む、組成物。 - 前記ポリペプチドが、以下の特徴:
i)少なくとも10−7のKDでActRIIリガンドに結合する、および
ii)細胞内のActRIIシグナル伝達を阻害する
のうち1つ以上を有する、請求項1に記載の組成物。 - 前記ポリペプチドが、ActRIIポリペプチドドメインに加えて、インビボ安定性、インビボ半減期、取り込み/投与、組織局在化もしくは分布、タンパク質複合体の形成および/または精製のうちの1以上を増強する1以上のポリペプチド部分を含む融合タンパク質である、請求項1に記載の組成物。
- 前記融合タンパク質が、免疫グロブリンFcドメインおよび血清アルブミンからなる群より選択されるポリペプチド部分を含む、請求項1に記載の組成物。
- 前記ポリペプチドが、グリコシル化アミノ酸、PEG化アミノ酸、ファルネシル化アミノ酸、アセチル化アミノ酸、ビオチン化アミノ酸、脂質部分に結合されたアミノ酸または有機誘導体化因子に結合されたアミノ酸から選択される1以上の修飾されたアミノ酸残基を含む、請求項1に記載の組成物。
- 前記組成物が、血中のヘモグロビンレベルを増加させる、請求項1に記載の組成物。
- 貧血を処置するための組成物であって、該組成物は、有効量のアクチビン−ActRIIアンタゴニストを含む、組成物。
- 前記アクチビン−ActRIIアンタゴニストが、アクチビンまたはActRIIのアンタゴニストポリペプチドである、請求項7に記載の組成物。
- 前記アクチビン−ActRIIアンタゴニストポリペプチドが、以下:
a)配列番号2に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
b)配列番号3に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
c)配列番号2から選択される少なくとも50の連続するアミノ酸を含むポリペプチド;
d)配列番号16に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;
e)配列番号17に対して少なくとも90%同一なアミノ酸配列を含むポリペプチド;および
f)配列番号16から選択される少なくとも50の連続するアミノ酸を含むポリペプチド
からなる群より選択される、請求項8に記載の組成物。 - 前記アクチビン−ActRIIアンタゴニストポリペプチドが、以下の特徴:
i)少なくとも10−7のKDでActRIIリガンドに結合する、および
ii)細胞内のActRIIシグナル伝達を阻害する
のうち1つ以上を有する、請求項9に記載の組成物。 - 前記アクチビン−ActRIIアンタゴニストポリペプチドが、該アクチビン−ActRIIアンタゴニストポリペプチドに加えて、インビボ安定性、インビボ半減期、取り込み/投与、組織局在化もしくは分布、タンパク質複合体の形成および/または精製のうちの1以上を増強する1以上のポリペプチド部分を含む融合タンパク質である、請求項9に記載の組成物。
- 前記融合タンパク質が、免疫グロブリンFcドメインおよび血清アルブミンからなる群より選択されるポリペプチド部分を含む、請求項11に記載の組成物。
- 前記アクチビンまたはActRIIのアンタゴニストポリペプチドが、グリコシル化アミノ酸、PEG化アミノ酸、ファルネシル化アミノ酸、アセチル化アミノ酸、ビオチン化アミノ酸、脂質部分に結合されたアミノ酸または有機誘導体化因子に結合されたアミノ酸から選択される1以上の修飾されたアミノ酸残基を含む、請求項8に記載の組成物。
- 赤血球レベルを増加させる因子を同定する方法であって、該方法は、以下:
a)ActRIIポリペプチドのリガンド結合ドメインに対して、ActRIIリガンドと競合的に結合する試験因子を同定する工程;および
b)非ヒト動物における赤血球レベルに対する該因子の効果を評価する工程
を包含する、方法。 - ヒト患者における赤血球レベルを増加させるための医薬を作製するための、アクチビンまたはActRIIのアンタゴニストポリペプチドの使用。
- ヒト患者における赤血球レベルを増加させるための組成物であって、該組成物は、有効量のActRII−Fc融合タンパク質を含み、該ActRII−Fc融合タンパク質は、以下:
a)配列番号3のアミノ酸配列に対して少なくとも90%同一なアミノ酸配列、
b)配列番号3のアミノ酸配列に対して少なくとも95%同一なアミノ酸配列、
c)配列番号3のアミノ酸配列、
d)配列番号2のアミノ酸配列、
e)配列番号7のアミノ酸配列、
f)配列番号17のアミノ酸配列に対して少なくとも90%同一なアミノ酸配列、
g)配列番号17のアミノ酸配列に対して少なくとも95%同一なアミノ酸配列、
h)配列番号17のアミノ酸配列、
i)配列番号16のアミノ酸配列、
j)配列番号20のアミノ酸配列、および
k)配列番号21のアミノ酸配列
からなる群より選択されるアミノ酸配列を含む、組成物。 - 前記患者の骨格筋量の15%未満の増加をもたらす、請求項16に記載の組成物。
- 前記組成物が、約20〜30日の期間にわたって、前記患者において少なくとも100ng/mlの血清濃度に達するように投与されるものであることを特徴とする、請求項16に記載の組成物。
- 前記組成物が、前記患者において、100ng/ml〜1000ng/mlの範囲の血清濃度に達するように投与されるものであることを特徴とする、請求項16に記載の組成物。
- 前記ActRII−Fc融合タンパク質が、15日と30日との間の血清半減期を有する、請求項16に記載の組成物。
- 前記組成物が、週に1回以下の頻度で前記患者に投与されるものであることを特徴とする、請求項20に記載の組成物。
- 前記組成物が、月に1回以下の頻度で前記患者に投与されるものであることを特徴とする、請求項20に記載の組成物。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US87568206P | 2006-12-18 | 2006-12-18 | |
US60/875,682 | 2006-12-18 | ||
PCT/US2007/025868 WO2008076437A2 (en) | 2006-12-18 | 2007-12-18 | Activin-actrii antagonists and uses for increasing red blood cell levels |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013055102A Division JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Publications (3)
Publication Number | Publication Date |
---|---|
JP2010513506A JP2010513506A (ja) | 2010-04-30 |
JP2010513506A5 true JP2010513506A5 (ja) | 2012-02-09 |
JP5415279B2 JP5415279B2 (ja) | 2014-02-12 |
Family
ID=39183159
Family Applications (8)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2009542880A Active JP5415279B2 (ja) | 2006-12-18 | 2007-12-18 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2013055102A Active JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2013243668A Pending JP2014040483A (ja) | 2006-12-18 | 2013-11-26 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2015211115A Pending JP2016020391A (ja) | 2006-12-18 | 2015-10-27 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2017018409A Pending JP2017075187A (ja) | 2006-12-18 | 2017-02-03 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2017119494A Withdrawn JP2017155064A (ja) | 2006-12-18 | 2017-06-19 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2019044553A Withdrawn JP2019089850A (ja) | 2006-12-18 | 2019-03-12 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2021032007A Pending JP2021080290A (ja) | 2006-12-18 | 2021-03-01 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Family Applications After (7)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2013055102A Active JP5865281B2 (ja) | 2006-12-18 | 2013-03-18 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2013243668A Pending JP2014040483A (ja) | 2006-12-18 | 2013-11-26 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2015211115A Pending JP2016020391A (ja) | 2006-12-18 | 2015-10-27 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2017018409A Pending JP2017075187A (ja) | 2006-12-18 | 2017-02-03 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2017119494A Withdrawn JP2017155064A (ja) | 2006-12-18 | 2017-06-19 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2019044553A Withdrawn JP2019089850A (ja) | 2006-12-18 | 2019-03-12 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
JP2021032007A Pending JP2021080290A (ja) | 2006-12-18 | 2021-03-01 | アクチビン−ActRIIアンタゴニストおよび赤血球レベルを増加させるためのその使用 |
Country Status (29)
Country | Link |
---|---|
US (7) | US7988973B2 (ja) |
EP (6) | EP2124999B1 (ja) |
JP (8) | JP5415279B2 (ja) |
KR (6) | KR20210027508A (ja) |
CN (4) | CN104524548A (ja) |
AU (1) | AU2007334333B2 (ja) |
BR (1) | BRPI0720476B1 (ja) |
CA (1) | CA2672758C (ja) |
CO (1) | CO6230995A2 (ja) |
CR (1) | CR10889A (ja) |
DK (2) | DK2468290T3 (ja) |
EA (3) | EA035911B1 (ja) |
EC (1) | ECSP099514A (ja) |
ES (1) | ES2396734T3 (ja) |
HK (3) | HK1137368A1 (ja) |
HR (1) | HRP20121035T1 (ja) |
IL (5) | IL199451A (ja) |
ME (1) | ME02335B (ja) |
MX (1) | MX2009006651A (ja) |
MY (3) | MY188973A (ja) |
NZ (4) | NZ707292A (ja) |
PL (2) | PL2124999T3 (ja) |
PT (1) | PT2124999E (ja) |
RS (1) | RS52537B (ja) |
SG (1) | SG10201702157QA (ja) |
SI (1) | SI2124999T1 (ja) |
UA (2) | UA116871C2 (ja) |
WO (1) | WO2008076437A2 (ja) |
ZA (2) | ZA200904454B (ja) |
Families Citing this family (82)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US6989276B2 (en) | 2001-05-10 | 2006-01-24 | Battelle Energy Alliance, Llc | Rapid classification of biological components |
USRE46351E1 (en) | 2001-05-10 | 2017-03-28 | Battelle Energy Alliance, Llc | Antibody profiling sensitivity through increased reporter antibody layering |
CA2574777C (en) | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
US8128933B2 (en) | 2005-11-23 | 2012-03-06 | Acceleron Pharma, Inc. | Method of promoting bone growth by an anti-activin B antibody |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CA2672758C (en) * | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
US20100028332A1 (en) * | 2006-12-18 | 2010-02-04 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TW202021980A (zh) * | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
US20080286881A1 (en) * | 2007-05-14 | 2008-11-20 | Apel William A | Compositions and methods for combining report antibodies |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
CA2729054C (en) * | 2008-06-26 | 2019-09-03 | Acceleron Pharma Inc. | Antagonists of actriib and uses for increasing red blood cell levels |
EP2315602A4 (en) * | 2008-06-26 | 2011-11-02 | Acceleron Pharma Inc | METHOD OF DOSING AN ACTRIIB ANTAGONIST AND MONITORING TREATED PATIENTS |
US8216997B2 (en) | 2008-08-14 | 2012-07-10 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating anemia using a combination of GDF traps and erythropoietin receptor activators |
TW201919685A (zh) * | 2008-08-14 | 2019-06-01 | 美商艾瑟勒朗法瑪公司 | 使用gdf阱以增加紅血球水平 |
AU2015202035B2 (en) * | 2008-08-14 | 2017-03-23 | Acceleron Pharma Inc. | Use of GDF traps to increase red blood cell levels |
US20110262466A1 (en) * | 2008-10-16 | 2011-10-27 | The Trustees Of The University Of Pennsylvania | Compositions containing thrombomodulin domains and uses thereof |
BRPI0920962A2 (pt) | 2008-11-26 | 2016-07-12 | Amgen Inc | variantes de polipeptídeos receptores de activina iib e usos dos mesmos |
CA2749544A1 (en) | 2009-01-13 | 2010-07-22 | Acceleron Pharma Inc. | Methods for increasing adiponectin |
CA2764890A1 (en) * | 2009-06-08 | 2010-12-16 | Acceleron Pharma Inc. | Methods for increasing thermogenic adipocytes |
AU2010263182B2 (en) | 2009-06-12 | 2016-05-12 | Acceleron Pharma Inc. | Truncated ActRIIB-Fc fusion proteins |
AU2010282361B2 (en) * | 2009-08-13 | 2015-03-19 | Acceleron Pharma Inc. | Combined use of GDF traps and erythropoietin receptor activators to increase red blood cell levels |
WO2011031901A1 (en) * | 2009-09-09 | 2011-03-17 | Acceleron Pharma Inc. | Actriib antagonists and dosing and uses thereof |
US8969009B2 (en) * | 2009-09-17 | 2015-03-03 | Vicki S. Thompson | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
US9410965B2 (en) * | 2009-09-17 | 2016-08-09 | Battelle Energy Alliance, Llc | Identification of discriminant proteins through antibody profiling, methods and apparatus for identifying an individual |
EP3260130B1 (en) * | 2009-11-03 | 2021-03-10 | Acceleron Pharma Inc. | Methods for treating fatty liver disease |
US8710016B2 (en) | 2009-11-17 | 2014-04-29 | Acceleron Pharma, Inc. | ActRIIB proteins and variants and uses therefore relating to utrophin induction for muscular dystrophy therapy |
CA2807552A1 (en) | 2010-08-06 | 2012-02-09 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
WO2012027065A2 (en) * | 2010-08-27 | 2012-03-01 | Celgene Corporation | Combination therapy for treatment of disease |
CN104531812A (zh) | 2010-10-01 | 2015-04-22 | 现代治疗公司 | 设计核酸及其使用方法 |
WO2012064771A1 (en) | 2010-11-08 | 2012-05-18 | Acceleron Pharma, Inc. | Actriia binding agents and uses thereof |
WO2012135805A2 (en) | 2011-03-31 | 2012-10-04 | modeRNA Therapeutics | Delivery and formulation of engineered nucleic acids |
US9464124B2 (en) | 2011-09-12 | 2016-10-11 | Moderna Therapeutics, Inc. | Engineered nucleic acids and methods of use thereof |
RU2707251C2 (ru) | 2011-10-03 | 2019-11-25 | Модерна Терапьютикс, Инк. | Модифицированные нуклеозиды, нуклеотиды и нуклеиновые кислоты и их применение |
KR20140102759A (ko) | 2011-12-16 | 2014-08-22 | 모더나 세라퓨틱스, 인코포레이티드 | 변형된 뉴클레오사이드, 뉴클레오타이드 및 핵산 조성물 |
EP2833892A4 (en) | 2012-04-02 | 2016-07-20 | Moderna Therapeutics Inc | MODIFIED POLYNUCLEOTIDES FOR THE PRODUCTION OF PROTEINS AND PEPTIDES ASSOCIATED WITH ONCOLOGY |
US9878056B2 (en) | 2012-04-02 | 2018-01-30 | Modernatx, Inc. | Modified polynucleotides for the production of cosmetic proteins and peptides |
US9572897B2 (en) | 2012-04-02 | 2017-02-21 | Modernatx, Inc. | Modified polynucleotides for the production of cytoplasmic and cytoskeletal proteins |
US9283287B2 (en) | 2012-04-02 | 2016-03-15 | Moderna Therapeutics, Inc. | Modified polynucleotides for the production of nuclear proteins |
US9809636B2 (en) * | 2012-04-06 | 2017-11-07 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels comprising administering BMP9 |
GB201206559D0 (en) * | 2012-04-13 | 2012-05-30 | Ucl Business Plc | Polypeptide |
JP6214537B2 (ja) * | 2012-08-21 | 2017-10-25 | 国立大学法人九州大学 | 貧血患者の貧血の要因を検出するためのバイオマーカー |
AU2013334659B2 (en) * | 2012-10-24 | 2019-07-11 | Celgene Corporation | Biomarker for use in treating anemia |
CN112957462A (zh) | 2012-10-24 | 2021-06-15 | 细胞基因公司 | 用于治疗贫血的方法 |
KR102279522B1 (ko) | 2012-11-02 | 2021-07-19 | 셀진 코포레이션 | 골 및 다른 장애를 치료하기 위한 액티빈-actrii 길항제 및 용도 |
JP6144355B2 (ja) | 2012-11-26 | 2017-06-07 | モデルナティエックス インコーポレイテッドModernaTX,Inc. | 化学修飾mRNA |
SG11201505960VA (en) | 2013-02-01 | 2015-08-28 | Santa Maria Biotherapeutics Inc | Administration of an anti-activin-a compound to a subject |
US8980864B2 (en) | 2013-03-15 | 2015-03-17 | Moderna Therapeutics, Inc. | Compositions and methods of altering cholesterol levels |
US10323076B2 (en) | 2013-10-03 | 2019-06-18 | Modernatx, Inc. | Polynucleotides encoding low density lipoprotein receptor |
AU2015231022B2 (en) * | 2014-03-21 | 2021-02-04 | Acceleron Pharma, Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis by inhibiting activin B and/or GDF11 |
BR112016028520A2 (pt) | 2014-06-04 | 2017-10-24 | Acceleron Pharma Inc | métodos e composições para o tratamento de transtornos com polipeptídeos de folistatina |
US10010498B2 (en) | 2014-06-04 | 2018-07-03 | Acceleron Pharma Inc. | Methods for treatment of amyotrophic lateral sclerosis with follistatin fusion proteins |
TN2016000553A1 (en) * | 2014-06-13 | 2018-04-04 | Acceleron Pharma Inc | Methods and compositions for treating ulcers |
MA41052A (fr) * | 2014-10-09 | 2017-08-15 | Celgene Corp | Traitement d'une maladie cardiovasculaire à l'aide de pièges de ligands d'actrii |
EP3212213B1 (en) | 2014-10-30 | 2021-04-28 | Acceleron Pharma Inc. | Methods and compositions using gdf15 polypeptides for increasing red blood cells |
RS64214B1 (sr) * | 2014-12-03 | 2023-06-30 | Celgene Corp | Antagonisti aktivin-actrii i njihova primena u lečenju mijelodisplastičnog sindroma |
MA41119A (fr) * | 2014-12-03 | 2017-10-10 | Acceleron Pharma Inc | Méthodes de traitement de syndromes myélodysplasiques et d'anémie sidéroblastique |
CN107428818A (zh) * | 2015-01-29 | 2017-12-01 | 密西根州立大学校董会 | 隐藏多肽及其用途 |
US20180031579A1 (en) | 2015-02-12 | 2018-02-01 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Methods for predicting the responsiveness of a patient affected with malignant hematological disease to chemotherapy treatment and methods of treatment of such disease |
US9975934B2 (en) | 2015-03-26 | 2018-05-22 | Acceleron Pharma Inc. | Follistatin-related fusion proteins |
BR112017021510A2 (pt) * | 2015-04-06 | 2018-07-03 | Acceleron Pharma Inc | heteromultímeros do receptor tipo i e tipo ii da superfamília tgf-beta e sua utilização |
KR20180006386A (ko) | 2015-04-22 | 2018-01-17 | 얼라이브젠 유에스에이 인코포레이티드 | 신규한 근육 소모 질환 치료용 하이브리드 actriib 리간드 트랩 단백질 |
US20180125928A1 (en) * | 2015-05-13 | 2018-05-10 | Celgene Corporation | Treatment of beta-thalassemia using actrii ligand traps |
EP3298034A4 (en) | 2015-05-20 | 2019-02-13 | Celgene Corporation | IN VITRO CELL CULTURE PROCEDURE FOR BETA THALASSEMIA BY MEANS OF ACTIVIN TYPE II RECEPTOR LIGANDS |
EP3321319B1 (en) * | 2015-07-06 | 2022-10-05 | Mitsubishi Gas Chemical Company, Inc. | Resin composition and prepreg, resin sheet, laminate plate, and printed circuit board |
US11123430B2 (en) | 2015-11-04 | 2021-09-21 | Acceleron Pharma Inc. | Methods for increasing red blood cell levels and treating ineffective erythropoiesis |
CN108697793B (zh) | 2015-11-23 | 2023-08-01 | 阿塞勒隆制药公司 | 治疗眼睛疾病的方法 |
EP3439741A4 (en) * | 2016-04-06 | 2020-05-06 | Acceleron Pharma Inc. | ALK7 ANTAGONISTS AND USES THEREOF |
WO2018013936A1 (en) | 2016-07-15 | 2018-01-18 | Acceleron Pharma Inc. | Compositions and methods for treating pulmonary hypertension |
JP6944768B2 (ja) | 2016-08-29 | 2021-10-06 | エア・ウォーター株式会社 | ペリクルの製造方法 |
EP3523328A4 (en) | 2016-10-05 | 2020-04-01 | Acceleron Pharma Inc. | ACTRIIB VARIANT PROTEINS AND USES THEREOF |
CN110461349A (zh) | 2016-11-10 | 2019-11-15 | 科乐斯疗法公司 | 激活素受体iia型变体及其使用方法 |
KR102628323B1 (ko) | 2017-03-24 | 2024-01-22 | 노바르티스 아게 | 심장질환 예방 및 치료 방법 |
KR20200085832A (ko) | 2017-11-09 | 2020-07-15 | 케로스 테라퓨틱스, 인크. | 액티빈 수용체 유형 iia 변이체 및 그의 사용 방법 |
AU2019206634B2 (en) | 2018-01-12 | 2024-06-27 | Keros Therapeutics, Inc. | Activin receptor type IIB variants and methods of use thereof |
EP3790572A4 (en) * | 2018-05-09 | 2022-03-16 | Keros Therapeutics, Inc. | TYPE IIA ACTIVIN RECEPTOR VARIANTS AND METHODS OF USE THEREOF |
IL293314A (en) | 2019-11-29 | 2022-07-01 | Kymab Ltd | Treatment of physiological iron overload |
CA3226249A1 (en) * | 2021-08-16 | 2023-02-23 | Thermolife International, Llc | Iron supplement compositions and methods of use thereof |
WO2023141724A1 (en) | 2022-01-28 | 2023-08-03 | 35Pharma Inc. | Activin receptor type iib variants and uses thereof |
Family Cites Families (81)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US71927A (en) * | 1867-12-10 | Improvement in apparatus fob turning on gas | ||
JPH0637520B2 (ja) | 1985-07-03 | 1994-05-18 | 味の素株式会社 | ポリペプチド |
US4973577A (en) | 1986-04-04 | 1990-11-27 | The Salk Institute For Biological Studies | FSH-releasing peptides |
US5080891A (en) | 1987-08-03 | 1992-01-14 | Ddi Pharmaceuticals, Inc. | Conjugates of superoxide dismutase coupled to high molecular weight polyalkylene glycols |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5096815A (en) | 1989-01-06 | 1992-03-17 | Protein Engineering Corporation | Generation and selection of novel dna-binding proteins and polypeptides |
US5198346A (en) | 1989-01-06 | 1993-03-30 | Protein Engineering Corp. | Generation and selection of novel DNA-binding proteins and polypeptides |
WO1992004913A1 (en) * | 1990-09-13 | 1992-04-02 | Children's Hospital Medical Center Of Northern California | Method for increasing red blood cell production by treatment with activin or activin-related peptides |
US5118667A (en) | 1991-05-03 | 1992-06-02 | Celtrix Pharmaceuticals, Inc. | Bone growth factors and inhibitors of bone resorption for promoting bone formation |
US6162896A (en) | 1991-05-10 | 2000-12-19 | The Salk Institute For Biological Studies | Recombinant vertebrate activin receptors |
US5885794A (en) | 1991-05-10 | 1999-03-23 | The Salk Institute For Biological Studies | Recombinant production of vertebrate activin receptor polypeptides and identification of receptor DNAs in the activin/TGF-β superfamily |
AU654724B2 (en) | 1991-05-10 | 1994-11-17 | Salk Institute For Biological Studies, The | Cloning and recombinant production of receptor(s) of the activin/TGF-beta superfamily |
US6692925B1 (en) | 1992-11-17 | 2004-02-17 | Ludwig Institute For Cancer Research | Proteins having serine/threonine kinase domains, corresponding nucleic acid molecules, and their use |
US5677196A (en) | 1993-05-18 | 1997-10-14 | University Of Utah Research Foundation | Apparatus and methods for multi-analyte homogeneous fluoro-immunoassays |
US5831050A (en) | 1993-06-07 | 1998-11-03 | Creative Biomolecules, Inc. | Morphogen cell surface receptor |
JPH09503673A (ja) | 1993-10-14 | 1997-04-15 | プレジデント・アンド・フエローズ・オブ・ハーバード・カレツジ | ニューロン細胞の誘導および維持法 |
US5525490A (en) | 1994-03-29 | 1996-06-11 | Onyx Pharmaceuticals, Inc. | Reverse two-hybrid method |
US5658876A (en) | 1994-04-28 | 1997-08-19 | The General Hospital Corporation | Activin antagonists as novel contraceptives |
US5814565A (en) | 1995-02-23 | 1998-09-29 | University Of Utah Research Foundation | Integrated optic waveguide immunosensor |
NZ306767A (en) | 1995-04-11 | 2000-03-27 | Univ Johns Hopkins | Method of identifying molecular interactions employing counterselection and at least two hybrid molecules or two hybrid systems |
EP0771873A3 (en) | 1995-10-27 | 1998-03-04 | Takeda Chemical Industries, Ltd. | Neuronal cell-specific receptor protein |
US6231880B1 (en) | 1997-05-30 | 2001-05-15 | Susan P. Perrine | Compositions and administration of compositions for the treatment of blood disorders |
US6696260B1 (en) | 1997-08-01 | 2004-02-24 | The Johns Hopkins University School Of Medicine | Methods to identify growth differentiation factor (GDF) binding proteins |
US6891082B2 (en) | 1997-08-01 | 2005-05-10 | The Johns Hopkins University School Of Medicine | Transgenic non-human animals expressing a truncated activintype II receptor |
US6656475B1 (en) | 1997-08-01 | 2003-12-02 | The Johns Hopkins University School Of Medicine | Growth differentiation factor receptors, agonists and antagonists thereof, and methods of using same |
AU8666398A (en) | 1997-08-01 | 1999-02-22 | Johns Hopkins University School Of Medicine, The | Methods to identify growth differentiation factor (gdf) receptors |
US6953662B2 (en) | 1997-08-29 | 2005-10-11 | Human Genome Sciences, Inc. | Follistatin-3 |
DE60027135T2 (de) | 1999-01-21 | 2007-01-11 | Metamorphix, Inc. | Inhibitoren für wachstumdifferenzierungsfaktor und ihre anwendungen |
EP1174149A1 (en) | 1999-04-19 | 2002-01-23 | Kyowa Hakko Kogyo Co., Ltd. | Proliferation inhibitor for androgen-independent tumor |
US6468543B1 (en) | 1999-05-03 | 2002-10-22 | Zymogenetics, Inc. | Methods for promoting growth of bone using ZVEGF4 |
IL150198A0 (en) * | 1999-12-15 | 2002-12-01 | Res Dev Foundation | Betaglycan as an inhibin receptor and uses thereof |
JP4487376B2 (ja) | 2000-03-31 | 2010-06-23 | 味の素株式会社 | 腎疾患治療剤 |
EP2141243A3 (en) | 2000-10-16 | 2010-01-27 | Brystol-Myers Squibb Company | Protein scaffolds for antibody mimics and other binding proteins |
AU2002236558A1 (en) | 2000-12-01 | 2002-06-11 | Regents Of The University Of California | Method and composition for modulating bone growth |
TW200526779A (en) | 2001-02-08 | 2005-08-16 | Wyeth Corp | Modified and stabilized GDF propeptides and uses thereof |
US20030082630A1 (en) | 2001-04-26 | 2003-05-01 | Maxygen, Inc. | Combinatorial libraries of monomer domains |
EP1390497A2 (en) | 2001-05-25 | 2004-02-25 | Genset | Human cdnas and proteins and uses thereof |
AUPR638101A0 (en) | 2001-07-13 | 2001-08-09 | Bioa Pty Limited | Composition and method for treatment of disease |
US6855344B2 (en) | 2001-07-17 | 2005-02-15 | Integrated Chinese Medicine Holdings, Ltd. | Compositions and methods for prostate and kidney health and disorders, an herbal preparation |
US7320789B2 (en) | 2001-09-26 | 2008-01-22 | Wyeth | Antibody inhibitors of GDF-8 and uses thereof |
US6784154B2 (en) | 2001-11-01 | 2004-08-31 | University Of Utah Research Foundation | Method of use of erythropoietin to treat ischemic acute renal failure |
US20030144203A1 (en) | 2001-12-19 | 2003-07-31 | Voyager Pharmaceutical Corporation | Methods for slowing senescence and treating and preventing diseases associated with senescence |
EP1572909A4 (en) | 2002-02-21 | 2007-06-06 | Wyeth Corp | PROTEIN CONTAINING A DOMAINE OF FOLLISTATIN |
US20030219846A1 (en) | 2002-02-28 | 2003-11-27 | Pfizer Inc. | Assay for activity of the ActRIIB kinase |
JP2004121008A (ja) * | 2002-09-30 | 2004-04-22 | Toray Ind Inc | ネコアクチビンaおよびそのサブユニット並びにその製造法 |
AR047392A1 (es) | 2002-10-22 | 2006-01-18 | Wyeth Corp | Neutralizacion de anticuerpos contra gdf 8 y su uso para tales fines |
US20040223966A1 (en) | 2002-10-25 | 2004-11-11 | Wolfman Neil M. | ActRIIB fusion polypeptides and uses therefor |
WO2004086953A2 (en) | 2003-03-26 | 2004-10-14 | The Board Of Trustees Of The University Of Arkansas | Method for diagnosis and treatment of bone turnover |
WO2005028517A2 (en) | 2003-05-09 | 2005-03-31 | The General Hospital Corporation | SOLUBLE TGF-β TYPE III RECEPTOR FUSION PROTEINS |
UA85055C2 (ru) | 2003-06-02 | 2008-12-25 | Уайт | Применение ингибиторов миостатика (gdf8) в сочетании с кортикостероидами для лечения нервно-мышечных заболеваний |
WO2005009460A2 (en) * | 2003-07-25 | 2005-02-03 | Medexis, S.A. | Pharmaceutical composition comprising activin a, alk-4 or derivatives thereof for the treatment of ophthalmic disorders or cancer |
JP2007530055A (ja) | 2004-03-26 | 2007-11-01 | アクセルロン ファーマ インコーポレーテッド | Bmp−3プロペプチドおよび関連する方法 |
CA2561809A1 (en) | 2004-03-31 | 2005-10-20 | Xencor, Inc. | Bmp-7 variants with improved properties |
US7465706B2 (en) | 2004-06-24 | 2008-12-16 | Acceleron Pharma Inc. | GDF3 propeptides and related methods |
CA2574777C (en) * | 2004-07-23 | 2015-09-01 | Acceleron Pharma Inc. | Actrii receptor polypeptides, methods and compositions |
WO2006039400A2 (en) | 2004-09-29 | 2006-04-13 | Mount Sinai School Of Medicine Of New York University | Fsh and fsh receptor modulator compositions and methods for inhibiting osteoclastic bone resorption and bone loss in osteoporosis |
JP2008520207A (ja) | 2004-11-16 | 2008-06-19 | アヴィディア リサーチ インスティテュート | タンパク質骨格およびその使用 |
NZ538097A (en) | 2005-02-07 | 2006-07-28 | Ovita Ltd | Method and compositions for improving wound healing |
JP5063366B2 (ja) | 2005-02-16 | 2012-10-31 | ザ ジェネラル ホスピタル コーポレイション | ヘプシジンによる鉄代謝を制御するためのTGF−βスーパーファミリーの化合物の調節因子の使用 |
CN101198321A (zh) * | 2005-04-26 | 2008-06-11 | 味之素株式会社 | 骨髓祖红细胞分化诱导剂 |
US8067562B2 (en) | 2005-11-01 | 2011-11-29 | Amgen Inc. | Isolated nucleic acid molecule comprising the amino acid sequence of SEQ ID NO:1 |
CN103432568A (zh) | 2005-11-23 | 2013-12-11 | 阿塞勒隆制药公司 | Activin-ActRIIa拮抗剂及其促进骨骼生长的应用 |
CA2856436A1 (en) | 2005-12-06 | 2007-06-14 | Amgen Inc. | Uses of myostatin antagonists |
JP4822562B2 (ja) | 2006-01-20 | 2011-11-24 | ベックマン コールター, インコーポレイテッド | 低ヘモグロビン濃度細胞百分率および鉄欠乏の検出における使用方法 |
JP2009536659A (ja) | 2006-05-09 | 2009-10-15 | ヘマクエスト・ファーマシューティカルズ,インコーポレーテッド | 血液疾患の治療法 |
CA2658465C (en) | 2006-07-21 | 2016-06-14 | Stephen C. Tarallo | Liquid compositions of calcium acetate |
CL2007002567A1 (es) | 2006-09-08 | 2008-02-01 | Amgen Inc | Proteinas aisladas de enlace a activina a humana. |
US7547781B2 (en) | 2006-09-11 | 2009-06-16 | Curis, Inc. | Quinazoline based EGFR inhibitors containing a zinc binding moiety |
WO2008060139A1 (en) | 2006-11-17 | 2008-05-22 | Erasmus University Medical Center Rotterdam | Methods for controlling mineralization of extracellular matrix, therapeutic methods based thereon and medicaments for use therein |
US8895016B2 (en) * | 2006-12-18 | 2014-11-25 | Acceleron Pharma, Inc. | Antagonists of activin-actriia and uses for increasing red blood cell levels |
CA2672758C (en) | 2006-12-18 | 2019-07-30 | Acceleron Pharma Inc. | Activin-actrii antagonists and uses for increasing red blood cell levels |
MX2009008222A (es) | 2007-02-01 | 2009-10-12 | Acceleron Pharma Inc | Antagonistas de activina-actriia y usos para tratar o prevenir cancer de mama. |
TW202021980A (zh) | 2007-02-02 | 2020-06-16 | 美商艾瑟勒朗法瑪公司 | 衍生自ActRIIB的變體與其用途 |
KR20200054317A (ko) | 2007-02-09 | 2020-05-19 | 악셀레론 파마 인코포레이티드 | 액티빈-ActRⅡA 길항제 및 암 환자에서 골 생장을 촉진시키기 위한 이의 용도 |
TWI573802B (zh) | 2007-03-06 | 2017-03-11 | 安美基公司 | 變異之活動素受體多肽及其用途 |
JP2010529041A (ja) | 2007-06-01 | 2010-08-26 | ワイス・エルエルシー | Bmp−10活性を調整する方法および組成物 |
GB0715087D0 (en) | 2007-08-03 | 2007-09-12 | Summit Corp Plc | Drug combinations for the treatment of duchenne muscular dystrophy |
AR068332A1 (es) | 2007-08-03 | 2009-11-11 | Summit Corp Plc | Combinaciones de drogas para el tratamiento de la distrofia muscular de duchenne |
CN103877564A (zh) | 2007-09-18 | 2014-06-25 | 阿塞勒隆制药公司 | 活化素-actriia拮抗剂和减少或抑制fsh分泌的用途 |
PE20091163A1 (es) | 2007-11-01 | 2009-08-09 | Wyeth Corp | Anticuerpos para gdf8 |
EP2283119B1 (en) | 2008-05-06 | 2015-01-07 | Joslin Diabetes Center, Inc. | Methods and compositions for inducing brown adipogenesis |
-
2007
- 2007-12-18 CA CA2672758A patent/CA2672758C/en active Active
- 2007-12-18 EA EA201201199A patent/EA035911B1/ru not_active IP Right Cessation
- 2007-12-18 PT PT78630688T patent/PT2124999E/pt unknown
- 2007-12-18 EP EP07863068A patent/EP2124999B1/en active Active
- 2007-12-18 NZ NZ707292A patent/NZ707292A/en unknown
- 2007-12-18 KR KR1020217005960A patent/KR20210027508A/ko not_active Application Discontinuation
- 2007-12-18 JP JP2009542880A patent/JP5415279B2/ja active Active
- 2007-12-18 KR KR1020157013795A patent/KR101803620B1/ko active IP Right Grant
- 2007-12-18 CN CN201410670950.5A patent/CN104524548A/zh active Pending
- 2007-12-18 WO PCT/US2007/025868 patent/WO2008076437A2/en active Application Filing
- 2007-12-18 PL PL07863068T patent/PL2124999T3/pl unknown
- 2007-12-18 KR KR1020207006948A patent/KR102223231B1/ko active IP Right Grant
- 2007-12-18 SG SG10201702157QA patent/SG10201702157QA/en unknown
- 2007-12-18 UA UAA201214689A patent/UA116871C2/uk unknown
- 2007-12-18 NZ NZ617196A patent/NZ617196A/en unknown
- 2007-12-18 EA EA202091230A patent/EA202091230A3/ru unknown
- 2007-12-18 KR KR1020167001731A patent/KR101831534B1/ko active IP Right Grant
- 2007-12-18 NZ NZ577847A patent/NZ577847A/en unknown
- 2007-12-18 RS RS20120548A patent/RS52537B/en unknown
- 2007-12-18 MY MYPI2016001928A patent/MY188973A/en unknown
- 2007-12-18 EP EP11195282A patent/EP2446896A1/en not_active Withdrawn
- 2007-12-18 AU AU2007334333A patent/AU2007334333B2/en active Active
- 2007-12-18 EP EP17182870.0A patent/EP3320911B1/en active Active
- 2007-12-18 DK DK11195130.7T patent/DK2468290T3/en active
- 2007-12-18 EP EP11195130.7A patent/EP2468290B1/en active Active
- 2007-12-18 KR KR1020097014226A patent/KR101688228B1/ko active IP Right Grant
- 2007-12-18 MY MYPI20092540A patent/MY162136A/en unknown
- 2007-12-18 EA EA200970603A patent/EA018037B1/ru unknown
- 2007-12-18 SI SI200731110T patent/SI2124999T1/sl unknown
- 2007-12-18 ME MEP-2016-200A patent/ME02335B/me unknown
- 2007-12-18 EP EP11195140.6A patent/EP2468291B1/en active Active
- 2007-12-18 DK DK07863068.8T patent/DK2124999T3/da active
- 2007-12-18 EP EP21205033.0A patent/EP4026553A1/en not_active Withdrawn
- 2007-12-18 MY MYPI2013002844A patent/MY170509A/en unknown
- 2007-12-18 KR KR1020187004410A patent/KR20180019768A/ko active Search and Examination
- 2007-12-18 BR BRPI0720476-0A patent/BRPI0720476B1/pt active IP Right Grant
- 2007-12-18 US US12/002,872 patent/US7988973B2/en active Active
- 2007-12-18 ES ES07863068T patent/ES2396734T3/es active Active
- 2007-12-18 CN CN201610145040.4A patent/CN105582521A/zh active Pending
- 2007-12-18 UA UAA200906746A patent/UA101309C2/ru unknown
- 2007-12-18 PL PL11195130T patent/PL2468290T3/pl unknown
- 2007-12-18 NZ NZ720955A patent/NZ720955A/en unknown
- 2007-12-18 CN CN201610144786.3A patent/CN105797135A/zh active Pending
- 2007-12-18 MX MX2009006651A patent/MX2009006651A/es active IP Right Grant
- 2007-12-19 CN CN200780051416.4A patent/CN101687015B/zh active Active
-
2008
- 2008-09-29 US US12/286,381 patent/US20100204092A1/en not_active Abandoned
- 2008-09-29 US US12/286,333 patent/US8007809B2/en active Active
-
2009
- 2009-06-18 IL IL199451A patent/IL199451A/en active IP Right Grant
- 2009-06-24 CR CR10889A patent/CR10889A/es unknown
- 2009-06-25 ZA ZA2009/04454A patent/ZA200904454B/en unknown
- 2009-07-09 CO CO09071017A patent/CO6230995A2/es not_active Application Discontinuation
- 2009-07-14 EC EC2009009514A patent/ECSP099514A/es unknown
-
2010
- 2010-06-01 HK HK10105399.4A patent/HK1137368A1/xx unknown
-
2011
- 2011-07-22 US US13/189,353 patent/US20120052067A1/en not_active Abandoned
-
2012
- 2012-03-19 ZA ZA2012/02027A patent/ZA201202027B/en unknown
- 2012-12-14 HR HRP20121035TT patent/HRP20121035T1/hr unknown
-
2013
- 2013-03-18 JP JP2013055102A patent/JP5865281B2/ja active Active
- 2013-11-26 JP JP2013243668A patent/JP2014040483A/ja active Pending
-
2015
- 2015-08-12 IL IL240523A patent/IL240523A/en active IP Right Grant
- 2015-08-12 IL IL240524A patent/IL240524A/en active IP Right Grant
- 2015-10-22 HK HK15110382.8A patent/HK1209624A1/xx unknown
- 2015-10-27 JP JP2015211115A patent/JP2016020391A/ja active Pending
-
2017
- 2017-02-03 JP JP2017018409A patent/JP2017075187A/ja active Pending
- 2017-06-19 JP JP2017119494A patent/JP2017155064A/ja not_active Withdrawn
- 2017-12-11 IL IL256247A patent/IL256247B/en unknown
-
2018
- 2018-10-31 HK HK18113934.2A patent/HK1254840A1/zh unknown
-
2019
- 2019-01-04 US US16/240,276 patent/US20200031903A1/en not_active Abandoned
- 2019-03-12 JP JP2019044553A patent/JP2019089850A/ja not_active Withdrawn
-
2020
- 2020-12-23 US US17/132,024 patent/US20210355191A1/en not_active Abandoned
-
2021
- 2021-03-01 JP JP2021032007A patent/JP2021080290A/ja active Pending
- 2021-07-07 IL IL284693A patent/IL284693A/en unknown
- 2021-08-05 US US17/395,365 patent/US20220204588A1/en not_active Abandoned
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP2010513506A5 (ja) | ||
JP6807132B2 (ja) | 組換えエリスロポエチンと部分的に組合されたil−1インヒビターおよびtnfアンタゴニストの貧血治療用途 | |
JP2014040483A5 (ja) | ||
JP2011530599A5 (ja) | ||
JP2008500373A5 (ja) | ||
JP2013504589A5 (ja) | ||
US20110306550A1 (en) | Apoe analogs and methods for their use | |
HRP20121035T1 (hr) | Aktivin-actrii antagonisti i uporabe za lijeäśenje anemije | |
CA2964782A1 (en) | Pharmaceutical compositions comprising peptide variants and methods of use thereof | |
AU2005231822B2 (en) | Methods of reducing aggregation of IL-1ra | |
US11299528B2 (en) | Long acting TRAIL receptor agonists for treatment of autoimmune diseases | |
US11827690B2 (en) | ApoC-II mimetic peptides | |
JP2023061943A (ja) | ペプチド組成物 | |
JP2003533538A5 (ja) | ||
KR20070004781A (ko) | 인터페론-타우를 포함하는 약학적 조성물 | |
JPH02479A (ja) | snRNP−A抗原及びそのフラグメント | |
CA3049212A1 (en) | Pac1 receptor agonists (maxcaps) and uses thereof | |
DE60109412T2 (de) | Therapeutische peptide | |
JP2007515157A5 (ja) | ||
JP2000336038A (ja) | 肝臓保護剤 | |
RU2420308C2 (ru) | Стабилизированные композиции ил-21 | |
JP2017509602A5 (ja) | ||
RU2785401C2 (ru) | Направленная регенерация переломанной кости посредством стимуляции рецептора паратиреоидного гормона | |
JP3000033B2 (ja) | 牛の小型ピロプラズマ病原虫感染の予防に有効なペプチド | |
RU2014117975A (ru) | Гибридные белки и белковые конъюгаты на основе белков теплового шока-70 (бтш70) и способы их применения (варианты) |